{"id":"landiolol-hcl","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Landiolol selectively blocks beta-1 adrenergic receptors on cardiac tissue, reducing sympathetic stimulation and decreasing heart rate, contractility, and blood pressure. Its ultra-short half-life (approximately 4 minutes) allows for rapid onset and offset of effect, making it suitable for acute perioperative and critical care settings where quick titration is needed.","oneSentence":"Landiolol HCl is an ultra-short-acting beta-1 selective adrenergic antagonist that rapidly reduces heart rate and cardiac workload.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:14.049Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intraoperative and postoperative tachycardia"},{"name":"Atrial fibrillation with rapid ventricular response in perioperative settings"}]},"trialDetails":[{"nctId":"NCT04607122","phase":"PHASE3","title":"Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery","status":"COMPLETED","sponsor":"CMC Ambroise Paré","startDate":"2021-01-27","conditions":"Atrial Fibrillation, Cardiac Surgery","enrollment":400},{"nctId":"NCT05084118","phase":"PHASE3","title":"Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2021-10-21","conditions":"Atrial Fibrillation, Postoperative Complications","enrollment":164},{"nctId":"NCT01741519","phase":"PHASE1","title":"Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2012-12","conditions":"Healthy","enrollment":14},{"nctId":"NCT00212680","phase":"PHASE2","title":"Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan","status":"COMPLETED","sponsor":"Ono Pharma USA Inc","startDate":"1996-12","conditions":"Postoperative Supraventricular Tachyarrythmia","enrollment":100},{"nctId":"NCT00212654","phase":"PHASE2, PHASE3","title":"Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2001-06","conditions":"Postoperative Supraventricular Tachyarrythmia","enrollment":165},{"nctId":"NCT00311038","phase":"PHASE2","title":"Pilot Study of ONO-1101 in Patients Scheduled for Multi-slice CT","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2006-04","conditions":"Coronary Artery Disease","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rapibloc"],"phase":"phase_3","status":"active","brandName":"Landiolol HCl","genericName":"Landiolol HCl","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Landiolol HCl is a medication used to prevent atrial fibrillation after cardiac surgery. It is administered as a low-dose intravenous infusion.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}